Hipod-CV 50 Dry Syrup is a combination antibiotic formulation containing Cefpodoxime Proxetil 50 mg and Clavulanic Acid 31.25 mg per 5 ml of reconstituted suspension. Cefpodoxime Proxetil, a third-generation cephalosporin, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Cefpodoxime by preventing enzymatic degradation of the antibiotic, thereby extending its spectrum against beta-lactamase producing resistant strains. Hipod-CV 50 Dry Syrup is indicated for the treatment of various bacterial infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media caused by susceptible organisms. The dry syrup formulation is particularly suitable for pediatric patients and those who have difficulty swallowing tablets. The medication should be reconstituted with the appropriate amount of water prior to administration and dosed according to the severity of infection and patient weight. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort. Hypersensitivity reactions, though rare, necessitate immediate discontinuation and medical attention. Use of Hipod-CV 50 Dry Syrup should be guided by susceptibility testing and clinical judgment to minimize the development of resistance.